ARQ 621

ARQ 621 is an allosteric, potent and selective inhibitor of Eg5, a microtubule-based ATPase motor protein involved in cell division. Anti-tumor activity[1]. ARQ 621 is a kinesin inhibitor[2]. ARQ 621 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Product Specifications

CAS Number

[1095253-39-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335, H400, H410

Target

Kinesin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/arq-621.html

Purity

99.0

Solubility

DMSO : 110 mg/mL (ultrasonic)

Smiles

O=C(N(CCCN)[C@@H](C(N1NC2=CC=CC=C2)=NC3=C(C=CC(Cl)=C3)C1=O)CC#C)C4=CC=CC(Cl)=C4F

Molecular Formula

C28H24Cl2FN5O2

Molecular Weight

552.43

Precautions

H302, H315, H319, H335, H400, H410

References & Citations

[1]L. C. Chen, et al. First-in-human study with ARQ 621, a novel inhibitor of Eg5: Final results from the solid tumors cohort.J Clin Oncol. 2011, May (20) : 3076-3076.|[2]Lindsay S Roberts, et al. Mapping Novel Metabolic Nodes Targeted by Anti-Cancer Drugs that Impair Triple-Negative Breast Cancer Pathogenicity. ACS Chem Biol. 2017 Apr 21;12 (4) :1133-1140.